LENZ logo

LENZ
LENZ Therapeutics Inc.

1,267
Mkt Cap
$317.62M
Volume
234,923.00
52W High
$50.40
52W Low
$8.25
PE Ratio
-3.61
LENZ Fundamentals
Price
$9.86
Prev Close
$10.13
Open
$10.32
50D MA
$11.33
Beta
1.49
Avg. Volume
1.17M
EPS (Annual)
-$2.85
P/B
1.12
Rev/Employee
$125,578.95
$169.48
Loading...
Loading...
News
all
press releases
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the eight ratings firms that are currently covering the firm...
MarketBeat·6h ago
News Placeholder
More News
News Placeholder
LENZ Therapeutics (NASDAQ:LENZ) Price Target Cut to $48.00 by Analysts at HC Wainwright
HC Wainwright reduced their target price on LENZ Therapeutics from $56.00 to $48.00 and set a "buy" rating on the stock in a report on Tuesday...
MarketBeat·6h ago
News Placeholder
Aberdeen Group plc Increases Holdings in LENZ Therapeutics, Inc. $LENZ
Aberdeen Group plc lifted its position in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) by 274.4% during the fourth quarter, according to the company in its most recent filing with...
MarketBeat·12d ago
News Placeholder
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives Consensus Rating of "Moderate Buy" from Brokerages
Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) have earned an average rating of "Moderate Buy" from the eight brokerages that are covering the stock, MarketBeat.com reports. One...
MarketBeat·25d ago
News Placeholder
HC Wainwright Issues Positive Forecast for LENZ Earnings
LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Investment analysts at HC Wainwright increased their Q1 2026 earnings per share (EPS) estimates for LENZ Therapeutics in a report issued on...
MarketBeat·25d ago
News Placeholder
Citigroup Has Lowered Expectations for LENZ Therapeutics (NASDAQ:LENZ) Stock Price
Citigroup decreased their price objective on shares of LENZ Therapeutics from $52.00 to $26.00 and set a "buy" rating for the company in a report on Thursday...
MarketBeat·26d ago
News Placeholder
FY2028 EPS Forecast for LENZ Therapeutics Lowered by Analyst
LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - HC Wainwright lowered their FY2028 earnings per share (EPS) estimates for LENZ Therapeutics in a research note issued on Wednesday, March 25th. HC Wainwright analyst M. Caufield now anticipates that the company will earn $0.62 per share for the y...
MarketBeat·26d ago
News Placeholder
Bank of America Has Lowered Expectations for LENZ Therapeutics (NASDAQ:LENZ) Stock Price
Bank of America decreased their target price on shares of LENZ Therapeutics from $35.00 to $29.00 and set a "buy" rating on the stock in a research report on Wednesday...
MarketBeat·27d ago
News Placeholder
LENZ Therapeutics (NASDAQ:LENZ) Posts Earnings Results, Misses Expectations By $0.25 EPS
LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) posted its earnings results on Tuesday. The company reported ($1.16) EPS for the quarter, missing analysts' consensus estimates of ($0.91) by...
MarketBeat·28d ago
News Placeholder
LENZ Therapeutics Q4 Earnings Call Highlights
Executives from LENZ Therapeutics (NASDAQ:LENZ) used the company's latest earnings call to provide an update on the early U.S. launch of its presbyopia eye drop, emphasizing initial physician...
MarketBeat·28d ago
<
1
2
...
>

Latest LENZ News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.